• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma

  • in Uncategorized
  • — 15 Jan, 2018
Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma
OLYMPUS DIGITAL CAMERA
Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma
AudioMedica News
Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma
Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma
00:00 / 6:00
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-3506"/>

ATLANTA—Subcutaneous administration of the anti-CD 38 monoclonal antibody daratumumab could help more patients get this emerging therapy more easily for their advanced or recently-diagnosed multiple myeloma according to research reported from the Pavo study at the 2017 American Society of Hematology annual meeting.

Study author Ajai Chari MD, Associate Professor of Medicine and Director of Clinical Research in the Multiple Myeloma Program, at Mount Sinai Hospital in New York tells the Audio Journal of Oncology “These are really exciting results. This would be extremely practice changing. Daratumumab has moved from monotherapy in advanced disease to first relapse. And now—at this year’s ASH—we have newly diagnosed [myeloma]. That’s a lot of dara[tumumab] being used globally. And to be giving a more convenient, potentially safer, form of administration is really going to be very practice changing.”

Abstract 838: Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

READ MORE about the Pavo study in Oncology Times

You may also like...

  • Cardiovascular Medicine Cardiovascular Medicine 8 Jan, 2006
  • Subscribe to Audio Medica’s podcast coverage from The European Society of Cardiology Congress 2005, 3-7 September, Stockholm, Sweden Subscribe to Audio Medica’s podcast coverage from The European Society of Cardiology Congress 2005, 3-7 September, Stockholm, Sweden 10 Jan, 2006
  • Audio Journal of Oncology Breast Cancer Special 2005 Audio Journal of Oncology Breast Cancer Special 2005 15 Jan, 2006
  • Subscribe to Audio Medica’s podcast coverage from the American Heart Association Scientific Sessions 2005 Subscribe to Audio Medica’s podcast coverage from the American Heart Association Scientific Sessions 2005 8 Jan, 2006

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Childhood Obesity—Whose Business Is It?
  • Next story Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Childhood Obesity—Whose Business Is It?
    • Ibrutinib: New Frontline Standard for Chronic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Microbiome Diversity Key To Survival After…
    • Venetoclax Pro-Apoptotic Therapy Benefits Older…
  • Home
  • Uncategorized
  • Subcutaneous Daratumumab “Potential Game Changer” for Multiple Myeloma

© COPYRIGHT 2020 AUDIOMEDICA.COM.